Clarivate for Life Sciences & Healthcare

Cristián Madoery, Director of Segment Sales for Clarivate Life Sciences & Healthcare, participated in Close-Up International México’s Outlook 2024 event, where he shared key insights from the Clarivate Drugs to Watch 2024 report. ? Cristián's presentation shed light on trends in the global pharmaceutical pipeline, projected growth drivers through 2032, and emerging opportunities for innovation. He provided valuable perspectives on transforming the sector and emphasized the significant potential for impactful advancements. ? Interested in how your organization can engage with this innovation ecosystem? Contact us to learn more ??

Thank you to the esteemed industry leaders and experts – Alaa Darwish, Dr Srikanth Rajagopal, Mohamed Amir, Firat Incioglu, Rina Chotai, and Hasan Kapar – for joining us at the Waldorf Astoria DIFC in Dubai for a thought-provoking roundtable discussion on "Unlocking the Market: Strategies for Pharmaceutical Pricing, Access, and Tenders in the GCC" earlier this month. The event provided a valuable platform to examine the critical role of national tenders in improving access to safe and effective medicines across the region. Experts engaged in an insightful dialogue on the current state of tender practices, delving into the evolution of these systems and their impact on the pharmaceutical industry, particularly in relation to various drug types. The conversation also focused on identifying key principles and best practices for designing a national tender system that ensures fair pricing, accessibility, and operational efficiency. Stay tuned for a report highlighting the key discussion topics and emerging trends. Discover more about Clarivate’s market-leading intelligence and transformative data technology here: https://lnkd.in/gD-vvkum #Pharmaceuticals #MarketAccess #Healthcare #Tenders #PharmaStrategy #HealthcareInnovation #Dubai

How will the approval of the first RSV vaccines transform care for vulnerable populations? The FDA recently approved Arexvy? and Abrysvo?, groundbreaking vaccines targeting respiratory syncytial virus (RSV) for older adults and infants—two high-risk groups. These vaccines reached the market after only one RSV season of study, highlighting the urgent need to address this health threat. However, both sponsors must conduct additional studies to evaluate long-term safety and efficacy, especially concerning specific population risks. Our latest report explores the evolving disease and competitive landscape, regulatory strategies and key areas of focus such as safety, pharmacovigilance and efficacy considerations -- essential reading for those navigating the complexities of RSV prevention and vaccine regulation. Download the full report to learn more about the regulatory challenges and next steps for these groundbreaking vaccines: https://lnkd.in/e8X8jdG8 #Vaccines #FDAApproval #HealthcareInnovation #PublicHealth #RegulatoryAffairs #VaccineSafety #InfectiousDisease #HealthcareResearch

Join the Clarivate team - Rosario Critelli and Oliver Sless - at Radiological Society of North America (RSNA) 2024 (December 1-5). Connect with the team to explore how Clarivate can empower the radiology industry by fostering smarter connections between people and technology. We look forward to discussing how we support clients in optimizing radiology workflows, advancing imaging across subspecialties, enabling value-based care and leveraging the latest technological innovations. Let’s shape the future of radiology together. Book a meeting here: https://lnkd.in/eCQzDkzB #RSNA2024 #RadiologyInnovation #HealthcareTech #ClinicalApplications #ValueBasedCare

The future of the pharmaceutical industry is being defined today. Join Clarivate experts— Madhurima Datta, Reena V Gupta, Soumik Das, Manushi Vachhrajani, and Ramandeep Singh—at CPHI India 2024, happening now through November 28 in Delhi. ? Discover how emerging trends and strategic collaboration can drive growth and innovation in the industry. Learn how Clarivate’s market-leading intelligence and transformative data solutions are helping shape the trajectory of pharmaceuticals worldwide. ? Book a meeting with our team here: https://lnkd.in/eq3kbvT4 #CPhIIndia #Pharmaceuticals #Innovation #Collaboration #PharmaLeadership

The growing interest in middle meningeal artery embolization for treating chronic subdural hematoma is fueled by encouraging preliminary results from the EMBOLISE, STEM and MAGIC-MT trials. This surge in physician engagement is anticipated to drive a substantial 13.6% global growth in these procedures from 2023 to 2028. In developed markets, there will likely be an increased adoption of specialty liquid embolics, while cost-sensitive markets may lean towards embolic glues and PVA particles. For an overview of key trends, clinical trial impacts, manufacturers and more, click here: https://lnkd.in/e-uivPVp #Embolization #ChronicSubduralHematoma #MedtechInsights

Favorable reimbursement and cost-effectiveness over surgical aortic valve replacement (SAVR) support the adoption of Transcatheter heart valves (THV). Building on the tremendous market success of transcatheter aortic valve replacement (TAVR), several more transcatheter valve replacement technologies are expected to chart similar market growth trajectories. Read more on cardiovascular medical device market trends here: https://lnkd.in/ddTJy5NA #CardioVascular #MedtechInsights #MedicalDevices #MedtechInsights

Join Clarivate experts Madhurima Datta, Reena V Gupta, Soumik Das, Manushi Vachhrajani, Ramandeep Singh at CPHI India 2024, now through November 28 in Delhi. This is your chance to meet with our team and explore emerging trends in the pharmaceutical industry. Connect with leading experts, discuss collaboration opportunities and discover how Clarivate's transformative data can shape the future of the pharma world. Learn how our market-leading intelligence and transformative data technology can shape the industry’s trajectory. Book a meeting with our team here: https://lnkd.in/eq3kbvT4 #CPhIIndia #Pharmaceuticals #Networking #Innovation #Collaboration #pharma

Thank you to everyone who connected with us at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024 in Barcelona. The event provided an excellent opportunity to engage with healthcare leaders, researchers, and policymakers from across the globe, driving forward important conversations in Health Economics and Outcomes Research (HEOR). Our team— Alison Isherwood, Brigitte Moore, Catherine Bottomley, Ciaran Cassidy, Ilias Paniaras, Nicki Hoskins, Richard Massey, Sarah Knight, Sonia Alesso, Stacey Chang-Douglass, and Sunita Nair—was delighted to share insights on the latest trends shaping the future of healthcare. During the conference, Alison, Brigitte, Catherine, Nicki, Stacey, and Sunita presented their research during the poster sessions adding invaluable insight to the on-going discussion of patient outcomes and healthcare value. Clarivate presentations highlighted diverse topics, including the use of qualitative research to identify key patient concepts, incorporating broader perspectives in health economic evaluations and AI-assisted reviews of NICE guidance for ultra-rare conditions. Discussions also explored the clinical, economic and humanistic burden of SIDS/SUID, risk factors for psoriasis, gene therapies for gliomas and the challenges of clinical endpoint heterogeneity in Crohn’s disease and ulcerative colitis. Navigate the evolving regulatory and commercial landscape with the support of our experts. Connect with the team here: https://lnkd.in/eFUWW4qi #HealthcareInnovation #HEOR #HealthEconomics #Networking #ISPOR2024 #GlobalHealth #HealthWellBeing

At the 2nd Pujiang Biopharmaceutical Original Innovation Forum, hosted by the Shanghai Biopharmaceutics Industry Association and co-organized by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Andrew O'Brien, Vice President, Life Sciences and Healthcare APAC at Clarivate, provided key insights on the growing emphasis of leading pharmaceutical companies on precision medicine and real-world data. Andrew highlighted the dynamic collaboration between pharmaceutical enterprises, universities, and R&D institutions, showcasing how innovation and R&D partnerships are increasingly shaped by evolving data trends. As global data mining accelerates, it is fueling drug innovation with a sharper focus on meeting clinical needs. By harnessing data to develop more efficient and precise treatment strategies, the pharmaceutical industry is advancing its ability to address unmet clinical challenges and improve patient outcomes. #PrecisionMedicine #RealWorldData #Pharmaceutical #Innovation #DataDriven